EP3440111C0 - ANTI-VEGFR-1 ANTIBODIES AND THEIR USES - Google Patents

ANTI-VEGFR-1 ANTIBODIES AND THEIR USES

Info

Publication number: EP3440111C0
Authority: EP; European Patent Office
Prior art keywords: vegfr; antibodies
Prior art date: 2016-04-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

EP17725339.0A

Other languages

German (de)

French (fr)

Other versions

EP3440111A1 (en

EP3440111B1 (en

Inventor

Sanjuan Pedro Miguel Lacal

Stefania D'atri

Veronica Morea

Lucio Tentori

Grazia Graziani

Federica Ruffini

Maria Cristina Failla

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fondazione Luigi Maria Monti

Universita degli Studi di Roma Tor Vergata

Original Assignee

Universita degli Studi di Roma Tor Vergata

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-05

Filing date

2017-04-05

Publication date

2023-12-20

2017-04-05 Application filed by Universita degli Studi di Roma Tor Vergata filed Critical Universita degli Studi di Roma Tor Vergata

2019-02-13 Publication of EP3440111A1 publication Critical patent/EP3440111A1/en

2023-12-20 Application granted granted Critical

2023-12-20 Publication of EP3440111B1 publication Critical patent/EP3440111B1/en

2023-12-20 Publication of EP3440111C0 publication Critical patent/EP3440111C0/en

Status Active legal-status Critical Current

2037-04-05 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP17725339.0A 2016-04-05 2017-04-05 Anti-vegfr-1 antibodies and uses thereof Active EP3440111B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITUA2016A002326A ITUA20162326A1 (en)	2016-04-05	2016-04-05	ANTI-VEGFR-1 ANTIBODIES AND USES OF THEM
PCT/IB2017/000379 WO2017175054A1 (en)	2016-04-05	2017-04-05	Anti-vegfr-1 antibodies and uses thereof

Publications (3)

Publication Number	Publication Date
EP3440111A1 EP3440111A1 (en)	2019-02-13
EP3440111B1 EP3440111B1 (en)	2023-12-20
EP3440111C0 true EP3440111C0 (en)	2023-12-20

Family

ID=56551475

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17725339.0A Active EP3440111B1 (en)	2016-04-05	2017-04-05	Anti-vegfr-1 antibodies and uses thereof

Country Status (3)

Country	Link
EP (1)	EP3440111B1 (en)
IT (1)	ITUA20162326A1 (en)
WO (1)	WO2017175054A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2024161009A1 (en)	2023-02-03	2024-08-08	Beech Biotech Sa	Compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2590671A1 (en) *	2004-11-18	2006-05-26	Imclone Systems Incorporated	Antibodies against vascular endothelial growth factor receptor-1
ITRM20060409A1 (en) *	2006-07-31	2008-02-01	Cnr Consiglio Naz Delle Ric Er	PRINCIPAL SEQUENCE ISOLATED IN THE DOMAIN THE IMMUNOGLOBULIN TYPE OF RECEIVER 1 OF THE VASCULAR END-PHYTOMIC GROWTH FACTOR AND BINDING THE INTEGRINE A5B1 TO PROANGIOGENIC ACTIVITY

2016
- 2016-04-05 IT ITUA2016A002326A patent/ITUA20162326A1/en unknown
2017
- 2017-04-05 WO PCT/IB2017/000379 patent/WO2017175054A1/en not_active Ceased
- 2017-04-05 EP EP17725339.0A patent/EP3440111B1/en active Active

Also Published As

Publication number	Publication date
EP3440111A1 (en)	2019-02-13
WO2017175054A1 (en)	2017-10-12
EP3440111B1 (en)	2023-12-20
ITUA20162326A1 (en)	2017-10-05

Legal Events

Date	Code	Title	Description
2017-06-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: UNKNOWN
2017-10-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-01-11	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-01-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-02-13	17P	Request for examination filed	Effective date: 20181031
2019-02-13	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-02-13	AX	Request for extension of the european patent	Extension state: BA ME
2019-07-10	DAV	Request for validation of the european patent (deleted)
2019-07-10	DAX	Request for extension of the european patent (deleted)
2019-08-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-09-11	17Q	First examination report despatched	Effective date: 20190807
2023-07-18	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-07-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2023-08-09	RIN1	Information on inventor provided before grant (corrected)	Inventor name: FAILLA, MARIA CRISTINA Inventor name: RUFFINI, FEDERICA Inventor name: GRAZIANI, GRAZIA Inventor name: TENTORI, LUCIO Inventor name: MOREA, VERONICA Inventor name: D'ATRI, STEFANIA Inventor name: LACAL SANJUAN, PEDRO MIGUEL
2023-08-16	INTG	Intention to grant announced	Effective date: 20230719
2023-08-16	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: UNIVERSITA DEGLI STUDI DI ROMA " TOR VERGATA" Owner name: FONDAZIONE LUIGI MARIA MONTI
2023-11-07	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2023-11-17	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2023-11-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2023-12-20	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-12-20	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2023-12-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2024-01-04	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602017077680 Country of ref document: DE
2024-01-17	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2024-02-21	U01	Request for unitary effect filed	Effective date: 20240111
2024-03-06	U07	Unitary effect registered	Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20240202
2024-04-08	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240321
2024-04-24	U20	Renewal fee for the european patent with unitary effect paid	Year of fee payment: 8 Effective date: 20240315
2024-04-26	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240321 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220
2024-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240320 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220
2024-07-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240420
2024-07-23	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220
2024-07-24	U1N	Appointed representative for the unitary patent procedure changed after the registration of the unitary effect	Representative=s name: PACE NAPOLEONE, MARIA; IT
2024-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220
2024-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240420 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220
2024-08-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220
2024-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220
2024-09-23	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602017077680 Country of ref document: DE
2024-10-25	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2024-10-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2024-11-20	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220
2024-11-27	26N	No opposition filed	Effective date: 20240923
2024-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220
2024-11-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2024-12-25	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20240405
2025-01-17	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240405
2025-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240405 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240430
2025-04-22	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240405
2025-05-21	U20	Renewal fee for the european patent with unitary effect paid	Year of fee payment: 9 Effective date: 20250417
2025-08-07	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20170405
2025-09-03	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20170405

Publication	Publication Date	Title
FR25C1020I1 (en)	2025-08-01	THERAPEUTIC ANTIBODIES AND THEIR USES
MA49537A (en)	2020-05-13	ANTI-LAG3 ANTIBODIES AND THEIR USES
EP3426288A4 (en)	2019-10-30	ANTI-PACAP ANTIBODIES AND USES THEREOF
EP3383916A4 (en)	2019-09-11	ANTI-CD73 ANTIBODIES AND USES THEREOF
MA47789A (en)	2020-01-22	ANTI-PHF-TAU ANTIBODIES AND THEIR USES
MA45235A (en)	2019-04-17	ANTI-C5 ANTIBODIES AND THEIR USES
MA46704A (en)	2019-09-11	ANTI-PYROGLUTAMATE- AMYLOID-BETA ANTIBODIES AND THEIR USES
MA49687A (en)	2020-06-03	ANTI-CTLA-4 ANTIBODIES AND THEIR USES
EP3389702A4 (en)	2019-08-14	ANTI-LAG-3 ANTIBODIES AND USES THEREOF
MA49683A (en)	2020-06-03	ANTI-CD8 ANTIBODIES AND THEIR USES
MA46708A (en)	2021-05-05	ANTI-PD1 ANTIBODIES AND THEIR USES
MA53184A (en)	2021-05-26	ANTI-OX40 ANTIBODIES AND THEIR USES
EP3328895A4 (en)	2019-08-21	ANTI-PD-L1 ANTIBODIES AND USES THEREOF
EP3377102C0 (en)	2023-08-09	ANTI-PD-1 ANTIBODIES AND THEIR THERAPEUTIC USES
MA45125A (en)	2021-06-02	ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND THEIR USES
MA49886A (en)	2020-06-24	ANTI-PAR2 ANTIBODIES AND THEIR USES
EP3283517A4 (en)	2019-03-06	ANTI-PACAP ANTIBODIES AND USES THEREOF
MA50397A (en)	2020-08-26	ANTI-BODY ANTI-TAU AND THEIR USES
MA50618A (en)	2020-08-12	POLYRHERAPIES AND THEIR USES
EP3356416A4 (en)	2019-04-10	ANTI-PD-1 ANTIBODIES AND USES THEREOF
MA42935A (en)	2018-08-01	OPTIMIZED ANTI-CD3 BISPECIFIC ANTIBODIES AND THEIR USES
EP3383904A4 (en)	2019-12-04	CTLA-4 ANTIBODIES AND USES THEREOF
MA46471A (en)	2021-05-19	ACTRIIB VARIANT PROTEINS AND THEIR USES
EP3362482A4 (en)	2019-08-07	ANTI-PCSK9 ANTIBODIES AND USES THEREOF
MA45233A (en)	2019-04-17	ANTI-GITR ANTIBODIES AND THEIR USES